Good news for #melanoma cancer patients: New results from a personalized #cancervaccine designed to prevent melanoma from returning after surgery showed positive results, according to research presented at this year’s #ESMO26 meeting in Madrid.

The study found that adding a specially tailored cancer vaccine to standard treatment with immunotherapy successfully reduced the risk of melanoma coming back by 42% compared with standard immunotherapy alone.

“The idea of this treatment is that by specifically boosting a patient’s immune system to recognize their own tumor cells, we can reduce the risk that the cancer comes back,” says Dr. Michael Postow, Chief of the Melanoma Service at MSK. “Even when we can’t see any cancer on a CT or PET scan, we know that often it’s still there — because such a high proportion of patients eventually have a cancer recurrence. That’s why there is tremendous need for this type of treatment.”

Read more about one of the three MSK patients treated in the trial: https://bit.ly/3W0Voj2